Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 51 - 100 av 114 resultater
Tid
Selskap
Tittel
Sektor
Kategori
24 Mar 2023
07:00 CET
CELYAD ONCOLOGY
Celyad Oncology Appoints Georges Rawadi as Its New CEO
20103010 Biotechnology
Corporate life
23 Mar 2023
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology publie ses résultats financiers pour l'année 2022 ainsi que les récents évènements marquants
20103010 Biotechnology
Other subject
23 Mar 2023
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology Reports Full Year 2022 Financial Results and Recent Business Highlights
20103010 Biotechnology
Other subject
17 Mar 2023
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology annoncera prochainement ses résultats opérationnels et financiers 2022 et organisera une conférence téléphonique
20103010 Biotechnology
Other subject
17 Mar 2023
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology to Announce Full Year 2022 Financial Results and Host Conference Call
20103010 Biotechnology
Other subject
15 Mar 2023
07:00 CET
CELYAD ONCOLOGY
Celyad Oncology Announces Non-Cash Impairment
20103010 Biotechnology
Change in Capital
15 Mar 2023
07:00 CET
CELYAD ONCOLOGY
Celyad annonce une réduction de valeur non monétaire
20103010 Biotechnology
Change in Capital
01 Mar 2023
07:00 CET
CELYAD ONCOLOGY
Celyad Oncology: Letter to Shareholders
20103010 Biotechnology
Corporate life
01 Mar 2023
07:00 CET
CELYAD ONCOLOGY
Celyad Oncology : Lettre aux Actionnaires
20103010 Biotechnology
Corporate life
09 Feb 2023
07:00 CET
CELYAD ONCOLOGY
Celyad Oncology Announces the Publication of Data From Its Phase 1 THINK Study of CYAD-01
20103010 Biotechnology
Other subject
09 Feb 2023
07:00 CET
CELYAD ONCOLOGY
Celyad Oncology annonce la publication des données de son étude clinique THINK de Phase 1 avec CYAD-01
20103010 Biotechnology
Other subject
03 Feb 2023
07:00 CET
CELYAD ONCOLOGY
Celyad Oncology Provides Fourth Quarter 2022 Business Update and 2023 Outlook
20103010 Biotechnology
Other subject
03 Feb 2023
07:00 CET
CELYAD ONCOLOGY
Celyad Oncology publie ses résultats financiers du quatrième trimestre 2022 et ses perspectives pour 2023
20103010 Biotechnology
Other subject
21 Dec 2022
07:00 CET
CELYAD ONCOLOGY
Celyad Oncology fait le point sur sa stratégie d’entreprise, en continuant de se concentrer sur les opportunités d'exploiter pleinement le véritable potentiel de ses plateformes technologiques propriétaires et de sa propriété intellectuelle
20103010 Biotechnology
New
21 Dec 2022
07:00 CET
CELYAD ONCOLOGY
Celyad Oncology Provides an Update on Its Strategic Business Model, Continuing to Focus on Opportunities to Fully Harness the True Potential of Its Proprietary Technology Platforms and Intellectual Property
20103010 Biotechnology
New
10 Nov 2022
07:01 CET
CELYAD ONCOLOGY
Celyad Oncology publie ses résultats financiers du troisième trimestre 2022 et les avancées récentes des activités de la Société
20103010 Biotechnology
New
10 Nov 2022
07:01 CET
CELYAD ONCOLOGY
Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights
20103010 Biotechnology
New
12 Oct 2022
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology Présente des Mises À Jour Stratégiques de ses Activités
20103010 Biotechnology
New
12 Oct 2022
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology Provides Strategic Update
20103010 Biotechnology
New
20 Sep 2022
07:02 CEST
CELYAD ONCOLOGY
Cellistic en Celyad Oncology kondigen GMP Celtherapie Manufacturing Operations-transactie aan
20103010 Biotechnology
New
20 Sep 2022
07:02 CEST
CELYAD ONCOLOGY
Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
20103010 Biotechnology
New
20 Sep 2022
07:02 CEST
CELYAD ONCOLOGY
Cellistic et Celyad Oncology annoncent une transaction relative aux opérations de production GMP de thérapie cellulaire
20103010 Biotechnology
New
05 Aug 2022
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology présente ses Résultats Financiers pour le premier semestre de l’année 2022 et les récents événements marquants de son activité
20103010 Biotechnology
Other subject
05 Aug 2022
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights
20103010 Biotechnology
Other subject
01 Aug 2022
07:01 CEST
CELYAD ONCOLOGY
La FDA lève la suspension clinique pour les essais de Phase 1b de CYAD-101-002 de Celyad Oncology
20103010 Biotechnology
Other subject
01 Aug 2022
07:01 CEST
CELYAD ONCOLOGY
Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial
20103010 Biotechnology
Other subject
28 Jul 2022
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology publiera prochainement les résultats financiers du premier semestre 2022 et tiendra une conférence téléphonique
20103010 Biotechnology
Other subject
28 Jul 2022
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call
20103010 Biotechnology
Other subject
24 Jun 2022
07:03 CEST
CELYAD ONCOLOGY
Celyad Oncology Announces Leadership Updates
20103010 Biotechnology
Other subject
24 Jun 2022
07:03 CEST
CELYAD ONCOLOGY
Celyad Oncology annonce des changements au niveau de sa direction
20103010 Biotechnology
Other subject
31 May 2022
08:00 CEST
CELYAD ONCOLOGY
Celyad: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
20103010 Biotechnology
New
31 May 2022
08:00 CEST
CELYAD ONCOLOGY
Celyad : Information relative au nombre total de Droits de Vote et d’Actions (Article 15 de la Loi du 2 Mai 2007)
20103010 Biotechnology
New
17 May 2022
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
20103010 Biotechnology
New
17 May 2022
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology donnera une présentation à la H.C. Wainwright Global Investment Conference
20103010 Biotechnology
New
05 May 2022
23:31 CEST
CELYAD ONCOLOGY
CORRECTING AND REPLACING: Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
20103010 Biotechnology
New
05 May 2022
23:31 CEST
CELYAD ONCOLOGY
CORRIGE ET REMPLACE : Celyad Oncology publie ses Résultats Financiers du Premier Trimestre 2022 et les avancées récentes de la Société
20103010 Biotechnology
New
05 May 2022
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
20103010 Biotechnology
New
05 May 2022
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology publie ses Résultats Financiers du Premier Trimestre 2022 et les avancées récentes de la Société
20103010 Biotechnology
New
24 Mar 2022
21:02 CET
CELYAD ONCOLOGY
Celyad Oncology présente ses Résultats Financiers pour l’année 2021 ainsi que les récents évènements marquants de son activité
20103010 Biotechnology
Other subject
24 Mar 2022
21:02 CET
CELYAD ONCOLOGY
Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
20103010 Biotechnology
Other subject
17 Mar 2022
07:01 CET
CELYAD ONCOLOGY
Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call
20103010 Biotechnology
Other subject
17 Mar 2022
07:01 CET
CELYAD ONCOLOGY
Celyad Oncology annoncera prochainement ses Résultats Opérationnels et Financiers 2021 et organisera une Conférence Téléphonique
20103010 Biotechnology
Other subject
02 Mar 2022
08:30 CET
CELYAD ONCOLOGY
Celyad Oncology annonce une suspension clinique de l’essai de Phase 1b CYAD-101-002
20103010 Biotechnology
New
02 Mar 2022
08:30 CET
CELYAD ONCOLOGY
Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial
20103010 Biotechnology
New
28 Feb 2022
08:32 CET
CELYAD ONCOLOGY
Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial
20103010 Biotechnology
Other subject
28 Feb 2022
08:32 CET
CELYAD ONCOLOGY
Celyad Oncology annonce une suspension volontaire de l’essai de Phase 1b CYAD-101-002
20103010 Biotechnology
Other subject
31 Jan 2022
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology Announces February 2022 Conference Schedule
20103010 Biotechnology
Other subject
31 Jan 2022
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology annonce sa participation à une conférence en février 2022
20103010 Biotechnology
Other subject
10 Jan 2022
07:01 CET
CELYAD ONCOLOGY
Celyad Oncology Partage Ses Perspectives Pour 2022
20103010 Biotechnology
Other subject
10 Jan 2022
07:01 CET
CELYAD ONCOLOGY
Celyad Oncology Provides Outlook for 2022
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva